## B. Braun Medical – Recall of ceftazidime

- On April 17, 2020, B. Braun Medical announced a voluntary, consumer-level recall of one lot of ceftazidime and dextrose for injection because test results were found to exceed the specification limits for High Molecular Weight Polymers (HMWP) at the nineteen month stability interval.

- The recalled product was distributed nationwide in the U.S. The affected recalled product includes the following lot number and expiration date:

| Product Description | NDC# | Lot# (Expiration Date) |
|---|---|---|
| Ceftazidime for Injection (2 g) and Dextrose for Injection (50 ml) in Duplex Container | 0264-3145-11 | H8J812 (7/31/2020) |

- Ceftazidime is indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: lower respiratory tract infections; skin and skin-structure infections; bacterial septicemia; bone and joint infections; gynecologic infections; intra-abdominal infections; and central nervous system infections.

- Elevated levels of HMWP have been shown to cause kidney damage and liver issues in animal studies. The impact of HMWP in humans is unknown.

- To date, B. Braun Medical has not received any adverse event reports related to this recall.

- Patients who have the recalled ceftazidime should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled ceftazidime.

- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.

- Contact B. Braun Medical by phone at **1-800-227-2862** for further information regarding this recall.